Recursion Pharmaceuticals Inc (RXRX) — Financial Flexibility Index
Recursion Pharmaceuticals Inc (RXRX) has a Financial Flexibility Index of -0.35x as of June 2026. Free cash flow of $-103.99 Million (operating CF $-105.95 Million minus capex $1.96 Million) represents 0% of total liabilities ($297.67 Million). Check Recursion Pharmaceuticals Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Recursion Pharmaceuticals Inc Financial Flexibility Index (2019–2025)
Historical Financial Flexibility Index trend for Recursion Pharmaceuticals Inc across 7 annual periods. For the full cash flow conversion analysis, see how efficiently does Recursion Pharmaceuticals Inc generate cash.
Annual Financial Flexibility Index for Recursion Pharmaceuticals Inc (2019–2025)
Year-by-year free cash flow to debt coverage for Recursion Pharmaceuticals Inc. Explore Recursion Pharmaceuticals Inc cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -1.06x | $-365.34 Million | $-371.81 Million | $343.26 Million | ▼ -27.5% |
| 2024 | -0.83x | $-345.48 Million | $-359.17 Million | $413.82 Million | ▲ +42.4% |
| 2023 | -1.45x | $-275.82 Million | $-287.78 Million | $190.26 Million | ▼ -576.7% |
| 2022 | -0.21x | $-46.16 Million | $-83.52 Million | $215.48 Million | ▲ +87.8% |
| 2021 | -1.76x | $-118.82 Million | $-158.61 Million | $67.41 Million | ▼ -2201.7% |
| 2020 | -0.08x | $-38.66 Million | $-45.40 Million | $504.87 Million | ▲ +67.5% |
| 2019 | -0.24x | $-53.13 Million | $-57.04 Million | $225.70 Million | — |